We are pleased to announce that we have entered into a joint research agreement with Teijin Pharma Ltd. (headquartered in Chiyoda-ku, Tokyo; Masaki Taneda, President & CEO; hereinafter referred to as Teijin Pharma). The purpose of this joint research is to identify novel drug target genes for neurological intractable diseases using Jiksak’s pre-synaptogenesis-inducing microbeads. This research is expected to play an important role in the elucidation of pathological conditions and the development of treatments. Jiksak and Teijin Pharma will contribute to the development of new treatments for neurological intractable diseases by utilizing cutting-edge biotechnology.
